Sleuth’s analysts take the strategy questions your team doesn’t have hours for, ahead of the board meeting, the fundraise, or the partnering push. You get a finished report or deck. The project behind it stays in your Studio account.
Sleuth’s analysts work from a knowledge base that’s already built and kept current, so their time goes to your question, not to gathering data. Your team stays on its longer-term work while we take the one-off questions.
A new idea from a conference or an investor meeting gets a structured analysis, while your scientists stay focused on the science and your strategists stay focused on the portfolio.
A competitor reports data and the board wants to know what it means for you, or a new head of R&D asks about the rest of the pipeline. You have a first read in days.
Your team is close to its programs, and AI tools tend to tell you what you want to hear. Sleuth’s analysts show where you stand, and test your plans against the evidence.
Every Concierge project ends in a polished report or deck. The datasets and documents behind it, quality checked by our analysts, are transferred to your Studio account.
A point of view you and your board can act on, with a source on every number.
The datasets built for your question, with a confidence score on every value.
The filings, trial records, and abstracts the analysts read, searchable in your project.
A consulting project ends with a deck that never changes. A Concierge project stays in your Studio account, so when the next question comes up, you start from the work that’s already done.
Sleuth watches every dataset around the clock and updates it as new trials, deals, and filings come in, then shows you what changed.
Ask for a new cut, another market, or the next slide in Studio, or in Claude and other AI tools, and it builds from the same data.
Over time, the updates and your team’s work point to something new. Take it on yourself, or send it back to us; it starts from the same foundation.
Read their reports to see what Concierge output looks like. Our analyst team comes from an investment banking and consulting background, and they work with Sleuth tools every day.

18,000+ Chinese assets and 335 deals, and why so few reach US approval.

Where ADC value is moving, now that a validated target is table stakes.

With injectables past 20% weight loss, the race moves to pills and persistence.

About 200 clinical degrader programs, and the one new target near approval.
Tell us the question, and we’ll tell you what it costs.
We scope it to one question and price it to match. You see the first findings and pressure-test the assumptions. Early-stage teams use it to get a board or investor deliverable without a consulting budget.
When a new project comes in, send it to the analysts on retainer in a shared Slack or Teams channel. Run one project at a time, as many as you need, without a new scope of work for each.

$5M+
In consulting fees avoided

“What makes Sleuth stand out is its rare combination of speed and credibility. The output is factual, well-structured, and decision-useful…”
Alex Cogdill
Head of Strategic Initiatives, Global BD, Daiichi Sankyo

Alex Cogdill
Head of Strategic Initiatives, Global BD, Daiichi Sankyo

“What makes Sleuth stand out is its rare combination of speed and credibility. The output is factual, well-structured, and decision-useful…”
$5M+
In consulting fees avoided

Before its first trial, a preclinical startup learned the real bar was keeping patients on the drug, and built its plan around it.

Before its raise, a seed-stage gene-editing company picked one lead program from about 11,700 diseases, with every value scored.
DART-Met
A Stanford researcher got a promising place to start in about a week, one he could prove sooner than the market he’d planned.